Price (delayed)
$1.59
Market cap
$30.98M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.02
Enterprise value
$20.43M
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). ...
Highlights
The quick ratio has soared by 103% year-on-year and by 16% since the previous quarter
The EPS has surged by 68% year-on-year and by 47% since the previous quarter
Key stats
What are the main financial stats of ANVS
MarketValuationsEarnings
Shares outstanding
19.49M
Market cap
$30.98M
Enterprise value
$20.43M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$26.69M
Net income
-$24.59M
EBIT
-$24.59M
EBITDA
-$24.59M
Free cash flow
-$21.89M
Per shareBalance sheetLiquidity
EPS
-$2.02
EPS diluted
-$2.31
Free cash flow per share
-$1.8
Book value per share
$0.67
Revenue per share
$0
TBVPS
$1.14
Total assets
$13.93M
Total liabilities
$4.62M
Debt
$0
Equity
$9.31M
Working capital
$10.04M
Debt to equity
0
Current ratio
3.59
Quick ratio
2.72
Net debt/EBITDA
0.43
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-239%
Return on equity
-873%
Return on invested capital
N/A
Return on capital employed
-244.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANVS stock price
How has the Annovis Bio stock price performed over time
Intraday
6.71%
1 week
-14.05%
1 month
-13.11%
1 year
-85.78%
YTD
-68.39%
QTD
6%
Financial performance
How have Annovis Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.69M
Net income
-$24.59M
Gross margin
N/A
Net margin
N/A
ANVS financials
The net income has soared by 56% year-on-year and by 40% since the previous quarter
The company's operating income rose by 41% YoY and by 12% QoQ
Growth
What is Annovis Bio's growth rate over time
ANVS growth chart
Valuation
What is Annovis Bio stock price valuation
P/E
N/A
P/B
2.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The EPS has surged by 68% year-on-year and by 47% since the previous quarter
Price to book (P/B)
The price to book (P/B) is 75% less than the 5-year quarterly average of 8.7
ANVS's equity is up by 32% since the previous quarter
Price to sales (P/S)
Efficiency
How efficient is Annovis Bio business performance
The company's return on equity has shrunk by 54% YoY
The return on assets is up by 45% since the previous quarter and by 27% year-on-year
Dividends
What is ANVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANVS.
Financial health
How did Annovis Bio financials performed over time
Assets vs liabilities
The quick ratio has soared by 103% year-on-year and by 16% since the previous quarter
ANVS's total liabilities has shrunk by 74% YoY and by 37% QoQ
Debt vs equity
The company's debt is 100% lower than its equity
ANVS's equity is up by 32% since the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.